Xing G, Zhang Y, Wu X, Wang H, Liu Y, Zhang Z
Evid Based Complement Alternat Med. 2022; 2021:4512755.
PMID: 34992665
PMC: 8727130.
DOI: 10.1155/2021/4512755.
Lashgari N, Roudsari N, Zandi N, Pazoki B, Rezaei A, Hashemi M
Mol Biol Rep. 2021; 48(1):855-874.
PMID: 33394234
DOI: 10.1007/s11033-020-06095-x.
Archambault A
Can Fam Physician. 2011; 36:343-51.
PMID: 21234051
PMC: 2280645.
Punchard N, Greenfield S, Thompson R
Mediators Inflamm. 1992; 1(3):151-65.
PMID: 18475455
PMC: 2365334.
DOI: 10.1155/S0962935192000243.
Gessell-Lee D, Popov V, Boldogh I, Olano J, Peterson J
Infect Immun. 2003; 71(11):6234-42.
PMID: 14573642
PMC: 219558.
DOI: 10.1128/IAI.71.11.6234-6242.2003.
Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis.
Rampton D, Sladen G, Youlten L
Gut. 1980; 21(7):591-6.
PMID: 7429322
PMC: 1419888.
DOI: 10.1136/gut.21.7.591.
Do prostaglandins cause gastrointestinal mucosal injury?.
Northway M, Castell D
Dig Dis Sci. 1981; 26(5):453-6.
PMID: 7249885
DOI: 10.1007/BF01313590.
Effect of prednisolone on prostaglandin synthesis by rectal mucosa in ulcerative colitis: investigation by laminar flow bioassay and radioimmunoassay.
Hawkey C, TRUELOVE S
Gut. 1981; 22(3):190-3.
PMID: 7227851
PMC: 1419508.
DOI: 10.1136/gut.22.3.190.
Imbalance of prostacyclin and thromboxane synthesis in Crohn's disease.
Hawkey C, Karmeli F, Rachmilewitz D
Gut. 1983; 24(10):881-5.
PMID: 6578172
PMC: 1420148.
DOI: 10.1136/gut.24.10.881.
Macrophage activation, chronic inflammation and gastrointestinal disease.
Tanner A, Arthur M, Wright R
Gut. 1984; 25(7):760-83.
PMID: 6376293
PMC: 1432607.
DOI: 10.1136/gut.25.7.760.
Prostaglandins and other mediators in food intolerance.
Lessof M, Anderson J
Clin Rev Allergy. 1984; 2(1):79-93.
PMID: 6201256
DOI: 10.1007/BF02991213.
Prostaglandins and ulcerative colitis.
Rampton D, Hawkey C
Gut. 1984; 25(12):1399-413.
PMID: 6150882
PMC: 1420195.
DOI: 10.1136/gut.25.12.1399.
Prostanoids cytoprotection for maintaining remission in ulcerative colitis. Failure of 15(R), 15-methylprostaglandin E2.
Goldin E, Rachmilewitz D
Dig Dis Sci. 1983; 28(9):807-11.
PMID: 6136395
DOI: 10.1007/BF01296903.
Inhibition of prostaglandin synthetase in human rectal mucosa.
Hawkey C, Lo Casto M
Gut. 1983; 24(3):213-7.
PMID: 6131017
PMC: 1419929.
DOI: 10.1136/gut.24.3.213.
Ulcerative colitis: effect of sulphasalazine, its metabolites and indomethacin on the ability of human colonic mucosa to metabolize prostaglandins in vitro.
Hillier K, Mason P, Pacheco S, Smith C
Br J Pharmacol. 1982; 76(1):157-61.
PMID: 6123357
PMC: 2068750.
DOI: 10.1111/j.1476-5381.1982.tb09201.x.
Increased suppressor cell activity in inflammatory bowel disease.
Holdstock G, Chastenay B, Krawitt E
Gut. 1981; 22(12):1025-30.
PMID: 6119275
PMC: 1419494.
DOI: 10.1136/gut.22.12.1025.
Inhibition of leucocyte motility by drugs used in ulcerative colitis.
Rhodes J, Bartholomew T, Jewell D
Gut. 1981; 22(8):642-7.
PMID: 6116649
PMC: 1420067.
DOI: 10.1136/gut.22.8.642.
Exaggerated prostaglandin production by colonic smooth muscle in rabbit colitis.
Kao H, Zipser R
Dig Dis Sci. 1988; 33(6):697-704.
PMID: 3163542
DOI: 10.1007/BF01540433.
Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.
Miyachi Y, Yoshioka A, Imamura S, Niwa Y
Gut. 1987; 28(2):190-5.
PMID: 2881849
PMC: 1432978.
DOI: 10.1136/gut.28.2.190.
Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid.
Peskar B, Dreyling K, Peskar B, May B, Goebell H
Agents Actions. 1986; 18(3-4):381-3.
PMID: 2875632
DOI: 10.1007/BF01965001.